Characterization of racemic species of chiral drugs using thermal analysis, thermodynamic calculation, and structural studies

Journal of Pharmaceutical Sciences

Volumn 88, Issue 3, 1999, Pages 337-346

  Li, Z Jane ^a   Zell, Mark T ^b   Munson, Eric J ^b   Grant, David J W ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRENOLOL; ATENOLOL; BEVANTOLOL; DROPROPIZINE; EPHEDRINE; IBUPROFEN; IOPANOIC ACID; MANDELIC ACID; METHYLEPHEDRINE; NOREPHEDRINE; PINDOLOL; PROPRANOLOL; PSEUDOEPHEDRINE; RAZOXANE; SOBREROL; SULPIRIDE;

ARTICLE; CHIRALITY; DRUG MANUFACTURE; DRUG PURIFICATION; ENTHALPY; ENTROPY; MELTING POINT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACEUTICAL ENGINEERING; RACEMIC MIXTURE; THERMODYNAMICS; X RAY DIFFRACTION;

EID: 0033046564     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980205u     Document Type: Article

References (31)

1. Millership, J. S.; Fitzpatrick, A. Commonly used chiral drugs: a survey. Chirality 1993, 5, 573-576.
2. Stinson, S. C.; Chiral drugs. Chem. Eng. News 1995, October 9, 44-47. Chiral drugs. Chem. Eng. News 1997, October 20, 38-70.
3. Stinson, S. C.; Chiral drugs. Chem. Eng. News 1995, October 9, 44-47. Chiral drugs. Chem. Eng. News 1997, October 20, 38-70.
4. Jacques, J.; Collet, A.; Wilen, S. H. Enantiomers, Racemates and Resolutions; John Wiley and Sons: New York, 1981 (reprint edition 1991, reissued with corrections, Krieger Publishing Co.: Malabar, FL, 1994).
5. A homochiral crystal is composed of a single enantiomer, whereas a heterochiral crystal contains both opposite enantiomers in the crystal lattice. A racemic conglomerate is an equimolar physical mixture of homochiral crystals of both enantiomers, while a racemic compound and a pseudoracemate are heterochiral crystals. In a racemic compound, the two opposite enantiomers are paired up in the unit cell of the crystal lattice, whereas in a pseudoracemate the opposite enantiomers are arranged more or less randomly as a solid solution.
6. Collet, A.; Ziminski, L.; Garcia, C.; Vigné-Maeder, F. Chiral discrimination in crystalline enantiomer systems: Facts, interpretations, and speculations. In NATO ASI series -Supramolecular Stereochemistry; Siegel, J. S., Ed.; Kluwer Academic: The Netherlands, 1995; pp 91-110.
7. Li, Z. J.; Grant, D. J. W. Relationship between crystal properties and physicochemical properties of chiral drugs. J. Pharm. Sci. 1997, 86, 1073-1078.
8. Prankerd, R. J.; Elsabee, M. Thermal analysis of chiral drug mixtures: The DSC behavior of mixtures of ephedrine-HCl and pseudoephedrine-HCL enantiomers. Thermochim. Acta 1995, 248, 147-160.
9. Neau, S. H.; Shinwari, M. K.; Hellmuth, E. W. Melting point phase diagrams of free base and hydrochloride salts of bevantolol, pindolol and propranolol. Int. J. Pharm. 1993, 99, 303-310.
10. Eliel, E. L.; Wilen, S. H.; Mander, L. N. Stereochemistry of Organic Compounds; John Wiley and Sons: New York, 1994.
11. Duddu, S. P.; Fung, F. K.-Y.; Grant, D. J. W. Effects of crystallization in the presence of the opposite enantiomer on the crystal properties of (SS)-(+)-pseudoephedrinium salicylate. Int. J. Pharm. 1996, 127, 53-63.
12. Li, Z. J.; Grant, D. J. W. Effects of excess enantiomers on the crystal properties of a racemic compound: ephedrinium 2-naphthalenesulfonate. Int. J. Pharm. 1996, 137, 21-31.
13. Touitou, E.; Chow, D. D.; Lawter, J. R. Chiral β-blockers for transdermal delivery. Int. J. Pharm. 1994, 104, 19-28.
14. Bettinetti, G.; Giordano, F.; Fronza, G.; Italia, A.; Pellegata, R.; Villa, M.; Ventura, P. Sobrerol enantiomers and racemates: solid-state spectroscopy, thermal behavior and phase diagrams. J. Pharm. Sci. 1990, 79, 470-475.
15. Pitre, D.; De Amici, M.; Colombo, M.; Gallo, G. G.; Nebuloni, M. Further characterization of the solid forms of iopanoic acid and its enantiomers. Arch. Pharm. 1992, 32, 385-388.
16. Pitre, D.; Stradi, R. Racemic modification of (R,S)-3-(4-phenyl-1-piperazinyl)-1,2-propandiol and melting point diagram. Arch. Pharm. 1990, 323, 23-25.
17. Pitre, D.; Valoti, E. Physical properties of sulpiride and its (S)-enantiomer. Arch. Pharm. 1987, 320, 859-861.
18. Vigevani, A.; Zampieri, M.; Pellizzato, R. Thermal behavior and binary phase diagram of (S)-(+)-4,4′-(1-methyl-1,2-ethandiol)-bis-(2,6-piperazinedione) (dex-razoxane), a cardio-protective agent, and its (R)-(-)-enantiomer. J. Pharm. Biomed. Anal. 1992, 10, 31-36.
19. Di Silvestro, G.; Palmisano, G.; Pellegata, R. Phase diagram of (R)- and (S)-hydroxy-2-pyrrolidone mixtures: A new case of a conglomerate forming system. J. Pharm. Sci. 1993, 82, 758-760.
20. (a) Li, Z. J. Implications of Chirality in the Physicochemical Properties and Crystallization of Chiral Drugs, Ph.D. Thesis, University of Minnesota, 1997.
21. (b) Li, Z. J.; Grant, D. J. W. A molecular modeling study of chiral drug crystals: structural analysis and lattice energy calculations. Pharm. Res. 1996, 13 Suppl., S-340, PDD-7430.
22. -1 (see ref 3).
23. 8 but no structural analysis was given. Because the material is not commercially available, further testing could not be performed.
24. Brock, C. P.; Schweizer, W. B.; Dunitz, J. D. On the validity of Wallach's rule: On the density and stability of racemic crystals compared with their chiral counterparts. J. Am. Chem. Soc. 1991, 113, 9811-9820.
25. Bugay, D. E. Solid-state nuclear magnetic resonance spectroscopy: theory and pharmaceutical applications. Pharm. Res. 1993, 10, 317-327.
26. Byrn, S. R. Solid-State Chemistry of Drugs; Academic Press: New York, 1982.
27. Etter, M. C.; Hoye, R. C.; Vojta, G. A. Solid-state NMR and X-ray crystallography: complementary tools for structure determination. Cryst. Rev. 1988, 1, 281-338.
28. Maciel, G. E.; Jagannathan, N. R.; Frye, J. S. Solid-state NMR: opportunities and challenges. In NMR and X-ray Crystallography: Interfaces and Challenges; Etter, M. C., Ed.; Trans. Am. Crystallogr. Assoc. 1988, 24, 1-23.
29. Mason, S. F. Molecular Optical Activity and Chiral Discriminations; Cambridge University Press: Cambridge, UK, 1982; p 171.
30. Coquerel, G.; Perez, G.; Hartman, P. Croissance d'un énantiomère en milieu quasi-racémique: cas du dichloroacétate de norfenfluramine. J. Cryst. Growth 1988, 88, 511-521.
31. Li, Z. J.; Grant, D. J. W. Thermal analysis as a method for characterizing racemic species. Pharm. Res. 1996, 13 Suppl., S-340, PDD-7429.